Cardioprotective Effects of Telmisartan against Heart Failure in Rats Induced By Experimental Autoimmune Myocarditis through the Modulation of Angiotensin-Converting Enzyme-2/Angiotensin 1-7/Mas Receptor Axis

Cardioprotective Effects of Telmisartan against Heart Failure in Rats Induced By Experimental Autoimmune Myocarditis through the Modulation of Angiotensin-Converting Enzyme-2/Angiotensin 1-7/Mas Receptor Axis

<p>Angiotensin-converting enzyme-2 (ACE-2) is a homolog of ACE that preferentially forms angiotensin-(ANG)-1-7 from angiotensin II (ANG II). We investigated the cardioprotective effects of telmisartan, a well-known angiotensin receptor blockers (ARBs) against experimental autoimmune myocarditi...

Full description

Bibliographic Details
Main Author:	Vijayakumar Sukumaran, Punniyakoti T. Veeraveedu, Narasimman Gurusamy, Ken'ichi Yamaguchi, Arun Prasath Lakshmanan, Meilei Ma, Kenji Suzuki, Makoto Kodama, Kenichi Watanabe
Format:	Article
Language:	English
Published:	Ivyspring International Publisher 2011-01-01
Series:	International Journal of Biological Sciences
Online Access:	http://www.biolsci.org/v07p1077.htm

Similar Items

Olmesartan, an AT1 Antagonist, Attenuates Oxidative Stress, Endoplasmic Reticulum Stress and Cardiac Inflammatory Mediators in Rats with Heart Failure Induced by Experimental Autoimmune Myocarditis
by: Vijayakumar Sukumaran, Kenichi Watanabe, Punniyakoti T. Veeraveedu, Narasimman Gurusamy, Meilei Ma, Rajarajan A. Thandavarayan, Arun Prasath Lakshmanan, Ken'ichi Yamaguchi, Kenji Suzuki, Makoto Kodama
Published: (2011-01-01)

Telmisartan inhibits the progression of cardiomyopathy in daunorubicin treated rats: the role of advanced glycation end products
by: Wawaimuli Arozal, et al.
Published: (2011-11-01)

Telmisartan and cardioprotection
by: McFarlane S
Published: (2011-11-01)

Curcumin ameliorates macrophage infiltration by inhibiting NF-κB activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy
by: Suzuki Kenji, et al.
Published: (2011-06-01)

Angiotensin receptor blocker telmisartan: efficacy, safety and relevance of clinical application
by: M L Maksimov, et al.
Published: (2017-03-01)

Angiotensin receptor blocker telmisartan: efficacy, safety and relevance of clinical application
by: Maksimov M.L., et al.
Published: (2017-02-01)

Angiotensin receptor blocker telmisartan suppresses renal gluconeogenesis during starvation
by: Tojo A, et al.
Published: (2015-02-01)

CARDIOPROTECTIVE AND NEPHROPROTECTIVE EFFECTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITOR RAMIPRIL
by: D. A. Napalkov, et al.
Published: (2016-01-01)

CARDIOPROTECTIVE AND NEPHROPROTECTIVE EFFECTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITOR RAMIPRIL
by: D. A. Napalkov, et al.
Published: (2016-01-01)

Attenuation of Immune-Mediated Renal Injury by Telmisartan, an Angiotensin Receptor Blocker and a Selective PPAR-γ Activator
by: Yuki Hamano, et al.
Published: (2011-09-01)

Review: Cardioprotective effects of telmisartan in uncomplicated and complicated hypertension
by: Guido Grassi, et al.
Published: (2008-06-01)

Effect of telmisartan, angiotensin‐converting enzyme inhibition, or both, on proteinuria and blood pressure in dogs
by: Brittany L. Fowler, et al.
Published: (2021-05-01)

Cardioprotective Effects of Qishenyiqi Mediated by Angiotensin II Type 1 Receptor Blockade and Enhancing Angiotensin-Converting Enzyme 2
by: Yong Wang, et al.
Published: (2012-01-01)

Angiotensin Converting Enzyme 2, Angiotensin-(1-7), and Receptor Mas Axis in the Kidney
by: Sergio Veloso Brant Pinheiro, et al.
Published: (2012-01-01)

Cardioprotection Conferred by Sitagliptin Is Associated with Reduced Cardiac Angiotensin II/Angiotensin-(1-7) Balance in Experimental Chronic Kidney Disease
by: Juliana Isa Beraldo, et al.
Published: (2019-04-01)

Corrigendum to “Cardioprotective Effects of Qishenyiqi Mediated by Angiotensin II Type 1 Receptor Blockade and Enhancing Angiotensin-Converting Enzyme 2”
by: Yong Wang, et al.
Published: (2019-01-01)

Characterization of the mas protein as an angiotensin ii receptor
by: Raynor, James E., Jr.
Published: (1994)

Angiotensin-(1-7) and Mas receptor in the brain
by: Natalia L. Rukavina Mikusic, et al.
Published: (2021-06-01)

Angiotensin-(1-7)/Angiotensin-Converting Enzyme 2/Mas Receptor Axis and Related Mechanisms
by: Anderson J. Ferreira, et al.
Published: (2012-01-01)

Adenoviral delivery of angiotensin-(1-7) or angiotensin-(1-9) inhibits cardiomyocyte hypertrophy via the mas or angiotensin type 2 receptor.
by: Monica Flores-Muñoz, et al.
Published: (2012-01-01)

Telmisartan, an Antagonist of Angiotensin II Receptors, Accentuates Voltage-Gated Na+ Currents and Hippocampal Neuronal Excitability
by: Ming-Chi Lai, et al.
Published: (2020-09-01)

Telmisartan protects chronic intermittent hypoxic mice via modulating cardiac renin-angiotensin system activity
by: Wanyu Wang, et al.
Published: (2018-07-01)

Telmisartan (micardis) - an antagonist of angiotensin II receptors of type 1: one more antihypertensivedrug or something greater?
by: I E Chazora
Published: (2003-06-01)

Haemodynamic and pulse wave responses to intravenous infusions of angiotensin II during chronic telmisartan therapy in normal volunteers
by: Noreen M Vingerhoedt, et al.
Published: (2003-12-01)

Mas-Mediated Antioxidant Effects Restore the Functionality of Angiotensin Converting Enzyme 2-Angiotensin-(1–7)-Mas Axis in Diabetic Rat Carotid
by: Larissa Pernomian, et al.
Published: (2014-01-01)

Potential of the Angiotensin Receptor Blockers (ARBs) Telmisartan, Irbesartan, and Candesartan for Inhibiting the HMGB1/RAGE Axis in Prevention and Acute Treatment of Stroke
by: Eiichiro Tanaka, et al.
Published: (2013-09-01)

Cardioprotective effects of angiotensin II type 1 receptor blockade with candesartan after reperfused myocardial infarction: role of angiotensin II type 2 receptor
by: Bodh I Jugdutt, et al.
Published: (2001-03-01)

Role of Angiotensin Converting Enzyme 2 and Mas in Diabetic Nephropathy
by: Wan-Yu Hsiu, et al.
Published: (2007)

Angiotensin 1-7 Protects against Angiotensin II-Induced Endoplasmic Reticulum Stress and Endothelial Dysfunction via Mas Receptor.
by: Dharmani Murugan, et al.
Published: (2015-01-01)

New Cardiovascular and Pulmonary Therapeutic Strategies Based on the Angiotensin-Converting Enzyme 2/Angiotensin-(1–7)/Mas Receptor Axis
by: Anderson J. Ferreira, et al.
Published: (2012-01-01)

Angiotensin II AT1 receptor blockade by telmisartan reduces impairment of spatial maze performance induced by both acute and chronic stress
by: Dominik Wincewicz, et al.
Published: (2015-09-01)

Antihypertensive and Angiotensin-I-Converting Enzyme (ACE)-Inhibitory Peptides from Fish as Potential Cardioprotective Compounds
by: Soheila Abachi, et al.
Published: (2019-10-01)

Cardioprotective effects of benazepril, an angiotensin-converting enzyme inhibitor, in an ischaemia-reperfusion model of myocardial infarction in rats
by: Kanhei Charan Sahoo, et al.
Published: (2009-12-01)

Update on the Angiotensin Converting Enzyme 2-Angiotensin (1-7)-Mas Receptor Axis: Fetal Programming, Sex Differences and Intracellular Pathways
by: Mark C. Chappell, et al.
Published: (2014-01-01)

Correction: Angiotensin 1-7 Protects against Angiotensin II-Induced Endoplasmic Reticulum Stress and Endothelial Dysfunction via Mas Receptor.
by: Dharmani Murugan, et al.
Published: (2016-01-01)

Angiotensin II type 1 receptor blockers favorably affect renal angiotensin II and MAS receptor expression in patients with diabetic nephropathy
by: Ye-Ping Ma, et al.
Published: (2020-05-01)

Telmisartan-induced sprue-like enteropathy: a case report and a review of patients using non-olmesartan angiotensin receptor blockers
by: Harshal Surendra Mandavdhare, et al.
Published: (2017-07-01)

Bioactive angiotensin peptides: focus on angiotensin IV
by: Tomris Mustafa, et al.
Published: (2001-12-01)

A Review of the Role of Bradykinin and Nitric Oxide in the Cardioprotective Action of Angiotensin-Converting Enzyme Inhibitors: Focus on Perindopril
by: Arnaud Ancion, et al.
Published: (2019-10-01)

Capacities of the current angiotensin-converting enzyme inhibitor zofenopril in clinical practice: cardioprotective, anti-ischemic, and antiatherogenic effects
by: M. G Bubnova
Published: (2013-03-01)